Ricerca avanzata

Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2016 Dicembre;107(6) > Minerva Medica 2016 Dicembre;107(6):381-91



Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Periodicità: Bimestrale

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2016 Dicembre;107(6):381-91


Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis

Ze X. ZHU 1, Ming H. LIAO 1, Xiao X. WANG 2, Ji W. HUANG 1

1 Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; 2 Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, China

INTRODUCTION: To compare radiofrequency ablation (RFA) plus ethanol injection (EI) with RFA alone for hepatocellular carcinoma.
EVIDENCE ACQUISITION: A comprehensive search of studies among PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Chinese BioMedical Literature Database (CBM) was conducted with published date from the earliest to May 1st, 2016. No language restrictions were applied, but only prospective randomized controlled trials (RCTs) or non-randomized controlled trials (non-RCTs) were eligible for a full-text review. Published trials that included a treatment group receiving RFA plus EI and a control group receiving RFA alone with data for at least 1-year survival or complete ablation rate were included. Pooled ORs with 95% confidence interval (CI) were calculated using either the fixed-effects model or random-effects model. All statistical analyses were carried out using Stata v.12.0 (Stata Corporation, College Station, TX, USA).
EVIDENCE SYNTHESIS: There were 8 trials (3 RCTs) involving 969 patients. Patients receiving RFA plus EI showed significantly better in 1-year survival rate (OR=2.09, 95% CI: 1.38-3.01; P<0.001), 2-year survival rate (OR=21.84, 95% CI: 1.13-3.00; P=0.014), 3-year survival rate (OR=1.86, 95% CI: 1.35-2.57; P<0.001) and complete ablation rate (OR=2.34, 95% CI: 1.52-3.61; P<0.001).
CONCLUSIONS: RFA plus EI was superior than RFA alone for treating HCC.

lingua: Inglese


inizio pagina